Want to see TPST full AI Analyst Report?
Top Page
Tempest Therapeutics
(NASDAQ:TPST)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.55
â–¼(-48.80% Downside)
Action:Reiterated
Date:10/21/26
The score is held down primarily by weak financial performance (no revenue, sizable losses/cash burn, and negative equity) and a bearish technical setup (price below key moving averages with negative MACD). Corporate events provide some offset via improved funding access and pipeline-related activity, but dilution and governance frictions remain meaningful risks, and valuation metrics offer limited support given negative earnings.
Positive Factors
Flexible Funding Access
The equity facility provides TPST with discretionary access to capital rather than requiring one immediate financing. That flexibility can help fund clinical development and corporate needs over several quarters, although using the facility would issue additional shares.
Negative Factors
Pre-Revenue Losses
TPST has no commercial revenue base to support its operating costs, and substantial recurring losses make financial performance dependent on future clinical success, commercialization, or partnering. Until one of those outcomes develops, profitability and operating leverage remain unavailable.
Read all positive and negative factors
Positive Factors
Negative Factors
Flexible Funding Access
The equity facility provides TPST with discretionary access to capital rather than requiring one immediate financing. That flexibility can help fund clinical development and corporate needs over several quarters, although using the facility would issue additional shares.
Read all positive factors
Tempest Therapeutics (TPST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.63M
Dividend YieldN/A
Average Volume (3M)5.24M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue GrowthN/A
EPS Growth69.34%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.48
Shares Outstanding16,889,767
10 Day Avg. Volume177,939
30 Day Avg. Volume5,242,553
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap2.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.07
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$7.00Price Target Upside548.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.85
Revenue Forecast (FY)N/A
Tempest Therapeutics Business Overview & Revenue Model
Company Description
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a...
Tempest Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.18M | 0.00 | -389.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -40.23M | -25.79M | -40.14M | -27.66M | -33.45M | -26.65M |
| Net Income | -40.47M | -26.26M | -41.84M | -29.49M | -35.71M | -28.30M |
Balance Sheet | ||||||
| Total Assets | 9.63M | 16.93M | 41.49M | 51.60M | 46.09M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 779.00K | 7.71M | 30.27M | 39.23M | 31.23M | 51.83M |
| Total Debt | 7.56M | 8.14M | 15.37M | 20.66M | 22.11M | 18.54M |
| Total Liabilities | 10.72M | 10.26M | 22.36M | 24.84M | 27.98M | 37.12M |
| Stockholders Equity | -1.09M | 6.67M | 19.13M | 26.77M | 18.11M | 36.12M |
Cash Flow | ||||||
| Free Cash Flow | -20.73M | -26.82M | -33.46M | -27.53M | -31.63M | -26.09M |
| Operating Cash Flow | -20.73M | -26.82M | -33.03M | -27.36M | -31.07M | -25.96M |
| Investing Cash Flow | 0.00 | 0.00 | -435.00K | -170.00K | -562.00K | -97.00K |
| Financing Cash Flow | 7.23M | 4.26M | 24.50M | 35.60M | 11.40M | 59.06M |
Tempest Therapeutics Technical Analysis
Negative
1.08
Price Trends
0.87
Negative
0.97
Negative
1.56
Negative
Market Momentum
-0.10
Positive
27.55
Positive
2.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 1.08 is above the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.87, and below the 200-day MA of 1.56, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 27.55 is Positive, neither overbought nor oversold. The STOCH value of 2.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.
Tempest Therapeutics Risk Analysis
Tempest Therapeutics disclosed 79 risk factors in its most recent earnings report. Tempest Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tempest Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $47.79M | 4.22 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $116.56M | -1.73 | -708.20% | ― | ― | 30.16% | |
42 Neutral | $8.63M | -0.11 | -1270.11% | ― | ― | 69.34% | |
42 Neutral | $8.40M | -0.18 | 3398.40% | ― | ― | 15.37% | |
41 Neutral | $9.49M | -0.39 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
TPST
Tempest Therapeutics
0.51
-10.50
-95.36%
ATNM
Actinium Pharmaceuticals
1.52
-0.01
-0.65%
PDSB
PDS Biotechnology
1.11
0.18
18.97%
LTRN
Lantern Pharma
0.64
-3.42
-84.32%
CALC
CalciMedica
1.23
-13.92
-91.88%
Tempest Therapeutics Corporate Events
Business Operations and StrategyShareholder Meetings
Tempest Therapeutics Faces Setback on Governance Reforms
Negative
Oct 20, 2026
On October 14, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally held on July 27, 2026, and previously adjourned on August 17 and September 15, to seek approval of an amendment removing certain supermajority voting...
Business Operations and StrategyExecutive/Board Changes
Tempest Therapeutics Adds Veteran Executive to Board
Positive
Oct 19, 2026
On October 13, 2026, Tempest Therapeutics appointed veteran financial and operating executive John W. Frederick as a Class III director on its board, with his term running until the 2027 annual meeting of stockholders. As a non-employee director, ...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Tempest Therapeutics Strengthens Governance and CAR-T Partnership Framework
Positive
Sep 28, 2026
On Sept. 22, 2026, Tempest Therapeutics entered into a Master Services Agreement with related-party Factor Bioscience Inc. to provide research and development services, including Work Order No. 1 for in vivo CAR-T therapy development, with expecte...
Business Operations and StrategyProduct-Related Announcements
Tempest Therapeutics Expands In Vivo CAR-T Collaboration
Positive
Sep 17, 2026
On September 14, 2026, Tempest Therapeutics entered an exclusive collaboration, option and license agreement with Hebei Senlang Biotechnology that grants Tempest a four-month exclusive option to license Senlang’s CD7-targeted lentiviral in v...
Business Operations and StrategyShareholder Meetings
Tempest Therapeutics Adjourns Meeting on Governance Changes
Negative
Sep 16, 2026
On September 15, 2026, Tempest Therapeutics reconvened a special shareholder meeting originally held on July 27 and August 17, 2026, to seek approval for an amendment to its Restated Certificate of Incorporation that would replace certain supermaj...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Tempest Therapeutics Announces New Private Warrant Financing
Positive
Sep 15, 2026
On September 11, 2026, Tempest Therapeutics entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and Series C and D common stock warrants, raising approximately $2.5 million in ...
Business Operations and StrategyExecutive/Board Changes
Tempest Therapeutics Announces New Chief Financial Officer
Neutral
Aug 24, 2026
On August 18, 2026, Tempest Therapeutics, Inc. disclosed that Principal Financial Officer and Principal Accounting Officer Justin Trojanowski had resigned from all his roles at the company, with the departure scheduled to take effect on September ...
Business Operations and StrategyShareholder Meetings
Tempest Therapeutics Adjourns Special Stockholder Meeting Again
Negative
Aug 18, 2026
On August 17, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally convened and adjourned on July 27, 2026, to seek approval of an amendment to its Restated Certificate of Incorporation that would replace certain supe...
Business Operations and StrategyPrivate Placements and Financing
Tempest Therapeutics Secures Flexible $50 Million Equity Facility
Positive
Aug 13, 2026
On August 13, 2026, Tempest Therapeutics entered into a purchase and registration rights agreement with Lincoln Park Capital Fund, under which Lincoln Park committed to buy up to $50 million of Tempest’s common stock over 24 months, starting...
Business Operations and StrategyShareholder Meetings
Tempest Therapeutics Adjourns Vote on Governance Changes
Neutral
Jul 28, 2026
On July 27, 2026, Tempest Therapeutics convened a special meeting of stockholders to seek approval of an amendment to its Restated Certificate of Incorporation that would eliminate certain supermajority voting requirements and allow stockholder ac...
Business Operations and StrategyProduct-Related Announcements
Tempest Therapeutics inks China in vivo CAR-T deal
Positive
Jul 22, 2026
On July 17, 2026, Tempest Therapeutics entered a collaboration agreement with Hebei Senlang Biotechnology to co-develop Tempest’s in vivo CAR-T product candidates in China, starting with TPST-4003. The deal positions Tempest to leverage Senl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.